Yeap Ng

National Institutes of Health
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (4)

Basal cell carcinoma (BCC), the most common human cancer, is driven by hyperactivation of the Hedgehog pathway mediated by Smoothened (SMO) signaling and Glioma-Associated Oncogene Homolog (GLI) transcription. Gαs and protein kinase A (PKA) negatively regulate Hedgehog signaling, offering a potential alternative BCC development and treatment pathway. In this study, using histology alongside bulk and single-cell RNA sequencing, we found that mouse BCC–like tumors that originate from Gαs pathway inactivation are highly similar to those driven by canonical Hedgehog signaling induced by constitutive SMO activation. Both pathways led to the expansion of basal stem cells in the skin, with tumor cells clustering in two distinct populations with markers for touch dome and isthmus stem cell–like cells. Interestingly, mutations that reduce Gαs and PKA activity were present in human BCC. Tumors from Gαs pathway inactivation were independent of the canonical Hedgehog regulators SMO and GPR161, establishing them as SMO-independent oncogenic Hedgehog signaling models. Finally, activation of the Gαs-coupled adenosine 2B receptor with BAY60-6583 counteracted oncogenic SMO, reducing Hedgehog signaling and tumor growth. Together, these findings offer a potential therapeutic strategy for BCC. Significance: Gαs/PKA pathway inactivation drives Hedgehog-dependent basal cell carcinoma and can be counteracted by activation of the Gαs-coupled adenosine 2B receptor to suppress tumor growth, providing a potential treatment for Hedgehog-driven tumors.

Year:

2026

Basal cell carcinoma (BCC), the most common human cancer, is driven by hyperactivation of the Hedgehog pathway mediated by Smoothened (SMO) signaling and Glioma-Associated Oncogene Homolog (GLI) transcription. Gαs and protein kinase A (PKA) negatively regulate Hedgehog signaling, offering a potential alternative BCC development and treatment pathway. In this study, using histology alongside bulk and single-cell RNA sequencing, we found that mouse BCC–like tumors that originate from Gαs pathway inactivation are highly similar to those driven by canonical Hedgehog signaling induced by constitutive SMO activation. Both pathways led to the expansion of basal stem cells in the skin, with tumor cells clustering in two distinct populations with markers for touch dome and isthmus stem cell–like cells. Interestingly, mutations that reduce Gαs and PKA activity were present in human BCC. Tumors from Gαs pathway inactivation were independent of the canonical Hedgehog regulators SMO and GPR161, establishing them as SMO-independent oncogenic Hedgehog signaling models. Finally, activation of the Gαs-coupled adenosine 2B receptor with BAY60-6583 counteracted oncogenic SMO, reducing Hedgehog signaling and tumor growth. Together, these findings offer a potential therapeutic strategy for BCC. Significance: Gαs/PKA pathway inactivation drives Hedgehog-dependent basal cell carcinoma and can be counteracted by activation of the Gαs-coupled adenosine 2B receptor to suppress tumor growth, providing a potential treatment for Hedgehog-driven tumors.

Year:

2026

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a potential cancer therapeutic that induces apoptosis in cancer cells while sparing the non-malignant cells in preclinical models. However, its efficacy in clinical trials has been limited, suggesting unknown modulatory mechanisms responsible for the lack of TRAIL activity in patients. Here, we hypothesized that TRAIL treatment elicits transcriptional changes in triple negative breast cancer (TNBC) cells that alter the immune milieu. To test this, we performed an RNAseq analysis of MDA-MB-231 cells treated with TRAIL, followed by validation in additional TNBC cell lines. TRAIL significantly induces expression of multiple cytokines such as CXCLs 1, 2, 3, 8,11 and IL-6, which are known to modify neutrophil function. Mechanistically, the induction of these cytokines was predominantly mediated by death receptor 5, caspase 8 (but not caspase 8 enzymatic activity), and the non-canonical NFKB2 pathway. The cytokines produced by the TRAIL-treated TNBC cells enhanced chemotaxis of healthy human donor isolated neutrophils. In vivo , TRAIL treated TNBC murine xenograft tumors showed activation of the NFKB2 pathway, elevated production of CXCLs and IL-6, and increased neutrophil recruitment into the tumors. Moreover, donor isolated neutrophils preincubated in supernatants from TRAIL-treated TNBC cells exhibited impaired cytotoxic effect against TNBC cells. Transcriptomic analysis of neutrophils incubated with either TRAIL alone or supernatant of TRAIL-treated TNBC cells revealed increased expression of inflammatory cytokines, immune modulatory genes, immune checkpoint genes, and genes implicated in delayed neutrophil apoptosis. Functional studies with these neutrophils confirmed their suppressive effect on T cell proliferation and an increase in Treg suppressive phenotype. Collectively, our study demonstrates a novel role of TRAIL-induced NFKB2-dependent cytokine production that promotes neutrophil chemotaxis and immune suppression.

Year:

2024

Year:

2020

Collaborators (10)

Yoshimi Greer

Staff Scientist

National Institutes of Health

UNITED STATES
View details

Roberto Weigert

Senior Investigator

National Institutes of Health

UNITED STATES
View details

Kavita Y. Sarin

-

UNITED STATES
View details

Saikat Mukhopadhyay

Associate Professor, W.W. Caruth, Jr. Scholar in Biomedical Research

University of Texas Southwestern Medical Center

UNITED STATES
View details

Daoud Meerzaman

Branch Chief and Director of research and development

National Cancer Institute

UNITED STATES
View details

Francesco RAIMONDI

Assistant Professor

Scuola Normale Superiore

ITALY
View details

Lisa A Ridnour

Staff Scientist

National Cancer Institute

UNITED STATES
View details

Stanley Lipkowitz

Chief

National Cancer Institute

UNITED STATES
View details

David Wink

Acting Deputy Chief

National Cancer Institute

UNITED STATES
View details

Manjari Kundu

National Institutes of Health

UNITED STATES
View details